首页 > 最新文献

Pharmacology & Therapeutics最新文献

英文 中文
microRNAs in kidney diseases: Regulation, therapeutics, and biomarker potential 肾脏疾病中的 microRNAs:调节、治疗和生物标记潜力。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-22 DOI: 10.1016/j.pharmthera.2024.108709

MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression by inhibiting the translation of their specific target messenger RNAs. To date, numerous studies have demonstrated changes in the expression of miRNAs in the kidneys throughout the progression of both acute kidney injury (AKI) and chronic kidney disease (CKD) in both human patients and experimental models. The role of specific microRNAs in the pathogenesis of kidney diseases has also been demonstrated. Further studies have elucidated the regulation of these microRNAs in diseased kidneys. Besides, certain miRNAs are detected in plasma and/or urine in kidney diseases and are potential diagnostic biomarkers. In this review, we provide an overview of recent developments in our understanding of how miRNAs contribute to kidney diseases. We also explore the potential of miRNAs as both biomarkers and therapeutic targets for these conditions, and highlight future research directions.

微小 RNA(miRNA)是一种非编码 RNA 小分子,通过抑制其特定目标信使 RNA 的翻译,在调节基因表达方面发挥着至关重要的作用。迄今为止,已有大量研究表明,在人类患者和实验模型中,在急性肾损伤(AKI)和慢性肾病(CKD)的整个进展过程中,肾脏中 miRNA 的表达都会发生变化。特定 microRNA 在肾脏疾病发病机制中的作用也已得到证实。进一步的研究阐明了这些 microRNA 在患病肾脏中的调控作用。此外,在肾脏疾病患者的血浆和/或尿液中检测到某些 miRNA,它们是潜在的诊断生物标志物。在这篇综述中,我们概述了在了解 miRNA 如何导致肾脏疾病方面的最新进展。我们还探讨了 miRNAs 作为这些疾病的生物标志物和治疗靶点的潜力,并强调了未来的研究方向。
{"title":"microRNAs in kidney diseases: Regulation, therapeutics, and biomarker potential","authors":"","doi":"10.1016/j.pharmthera.2024.108709","DOIUrl":"10.1016/j.pharmthera.2024.108709","url":null,"abstract":"<div><p>MicroRNAs (miRNAs) are small, non-coding RNA molecules that play a crucial role in regulating gene expression by inhibiting the translation of their specific target messenger RNAs. To date, numerous studies have demonstrated changes in the expression of miRNAs in the kidneys throughout the progression of both acute kidney injury (AKI) and chronic kidney disease (CKD) in both human patients and experimental models. The role of specific microRNAs in the pathogenesis of kidney diseases has also been demonstrated. Further studies have elucidated the regulation of these microRNAs in diseased kidneys. Besides, certain miRNAs are detected in plasma and/or urine in kidney diseases and are potential diagnostic biomarkers. In this review, we provide an overview of recent developments in our understanding of how miRNAs contribute to kidney diseases. We also explore the potential of miRNAs as both biomarkers and therapeutic targets for these conditions, and highlight future research directions.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142054567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeting organ-specific mitochondrial dysfunction to improve biological aging 针对器官特异性线粒体功能障碍改善生物衰老。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-22 DOI: 10.1016/j.pharmthera.2024.108710

In an aging society, unveiling new anti-aging strategies to prevent and combat aging-related diseases is of utmost importance. Mitochondria are the primary ATP production sites and key regulators of programmed cell death. Consequently, these highly dynamic organelles play a central role in maintaining tissue function, and mitochondrial dysfunction is a pivotal factor in the progressive age-related decline in cellular homeostasis and organ function.

The current review examines recent advances in understanding the interplay between mitochondrial dysfunction and organ-specific aging. Thereby, we dissect molecular mechanisms underlying mitochondrial impairment associated with the deterioration of organ function, exploring the role of mitochondrial DNA, reactive oxygen species homeostasis, metabolic activity, damage-associated molecular patterns, biogenesis, turnover, and dynamics.

We also highlight emerging therapeutic strategies in preclinical and clinical tests that are supposed to rejuvenate mitochondrial function, such as antioxidants, mitochondrial biogenesis stimulators, and modulators of mitochondrial turnover and dynamics. Furthermore, we discuss potential benefits and challenges associated with the use of these interventions, emphasizing the need for organ-specific approaches given the unique mitochondrial characteristics of different tissues.

In conclusion, this review highlights the therapeutic potential of addressing mitochondrial dysfunction to mitigate organ-specific aging, focusing on the skin, liver, lung, brain, skeletal muscle, and lung, as well as on the reproductive, immune, and cardiovascular systems. Based on a comprehensive understanding of the multifaceted roles of mitochondria, innovative therapeutic strategies may be developed and optimized to combat biological aging and promote healthy aging across diverse organ systems.

在老龄化社会中,揭示新的抗衰老战略以预防和抗击与衰老有关的疾病至关重要。线粒体是产生 ATP 的主要场所,也是细胞程序性死亡的关键调节器。因此,这些高度动态的细胞器在维持组织功能方面发挥着核心作用,而线粒体功能障碍是与年龄相关的细胞稳态和器官功能逐渐衰退的关键因素。本综述探讨了了解线粒体功能障碍与器官特异性衰老之间相互作用的最新进展。通过探讨线粒体 DNA 的作用、活性氧平衡、代谢活动、损伤相关分子模式、生物生成、周转和动力学,我们剖析了线粒体损伤与器官功能衰退相关的分子机制。我们还重点介绍了临床前和临床试验中有望恢复线粒体功能的新兴治疗策略,如抗氧化剂、线粒体生物生成刺激剂以及线粒体更替和动态调节剂。此外,我们还讨论了与使用这些干预措施相关的潜在益处和挑战,并强调鉴于不同组织线粒体的独特性,有必要采用针对特定器官的方法。总之,本综述强调了解决线粒体功能障碍以缓解器官特异性衰老的治疗潜力,重点关注皮肤、肝脏、肺、大脑、骨骼肌和肺,以及生殖、免疫和心血管系统。在全面了解线粒体多方面作用的基础上,可以开发和优化创新的治疗策略,以对抗生物衰老,促进不同器官系统的健康衰老。
{"title":"Targeting organ-specific mitochondrial dysfunction to improve biological aging","authors":"","doi":"10.1016/j.pharmthera.2024.108710","DOIUrl":"10.1016/j.pharmthera.2024.108710","url":null,"abstract":"<div><p>In an aging society, unveiling new anti-aging strategies to prevent and combat aging-related diseases is of utmost importance. Mitochondria are the primary ATP production sites and key regulators of programmed cell death. Consequently, these highly dynamic organelles play a central role in maintaining tissue function, and mitochondrial dysfunction is a pivotal factor in the progressive age-related decline in cellular homeostasis and organ function.</p><p>The current review examines recent advances in understanding the interplay between mitochondrial dysfunction and organ-specific aging. Thereby, we dissect molecular mechanisms underlying mitochondrial impairment associated with the deterioration of organ function, exploring the role of mitochondrial DNA, reactive oxygen species homeostasis, metabolic activity, damage-associated molecular patterns, biogenesis, turnover, and dynamics.</p><p>We also highlight emerging therapeutic strategies in preclinical and clinical tests that are supposed to rejuvenate mitochondrial function, such as antioxidants, mitochondrial biogenesis stimulators, and modulators of mitochondrial turnover and dynamics. Furthermore, we discuss potential benefits and challenges associated with the use of these interventions, emphasizing the need for organ-specific approaches given the unique mitochondrial characteristics of different tissues.</p><p>In conclusion, this review highlights the therapeutic potential of addressing mitochondrial dysfunction to mitigate organ-specific aging, focusing on the skin, liver, lung, brain, skeletal muscle, and lung, as well as on the reproductive, immune, and cardiovascular systems. Based on a comprehensive understanding of the multifaceted roles of mitochondria, innovative therapeutic strategies may be developed and optimized to combat biological aging and promote healthy aging across diverse organ systems.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S016372582400130X/pdfft?md5=8f87dab5dd66f3b5f2112c8e90a66766&pid=1-s2.0-S016372582400130X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C-type natriuretic peptide (CNP): The cardiovascular system and beyond C 型钠尿肽(CNP):心血管系统及其他
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-21 DOI: 10.1016/j.pharmthera.2024.108708

C-type natriuretic peptide (CNP) represents the ‘local’ member of the natriuretic peptide family, functioning in an autocrine or paracrine capacity to modulate a hugely diverse portfolio of physiological processes. Whilst the best-characterised of these regulatory roles are in the cardiovascular system, akin to its predominantly endocrine siblings atrial (ANP) and brain (BNP) natriuretic peptides, CNP governs many additional, unrelated mechanisms including bone growth, gamete maturation, auditory processing, and neuronal integrity. Furthermore, there is currently great interest in mimicking the biological activity of CNP for therapeutic gain in many of these disparate organ systems. Herein, we provide an overview of the physiology, pathophysiology and pharmacology of CNP in both cardiovascular and non-cardiovascular settings.

C 型利钠肽 (CNP) 是利钠肽家族中的 "本地 "成员,以自分泌或旁分泌的方式调节着多种多样的生理过程。CNP 在心血管系统中的调控作用最为突出,这与其主要作用于内分泌的同胞兄弟心房钠尿肽(ANP)和脑钠尿肽(BNP)类似,CNP 还能调控许多其他不相关的机制,包括骨骼生长、配子成熟、听觉处理和神经元完整性。此外,目前人们对模仿 CNP 的生物活性以在这些不同器官系统中获得治疗效果非常感兴趣。在此,我们将概述 CNP 在心血管和非心血管环境中的生理学、病理生理学和药理学。
{"title":"C-type natriuretic peptide (CNP): The cardiovascular system and beyond","authors":"","doi":"10.1016/j.pharmthera.2024.108708","DOIUrl":"10.1016/j.pharmthera.2024.108708","url":null,"abstract":"<div><p>C-type natriuretic peptide (CNP) represents the ‘local’ member of the natriuretic peptide family, functioning in an autocrine or paracrine capacity to modulate a hugely diverse portfolio of physiological processes. Whilst the best-characterised of these regulatory roles are in the cardiovascular system, akin to its predominantly endocrine siblings atrial (ANP) and brain (BNP) natriuretic peptides, CNP governs many additional, unrelated mechanisms including bone growth, gamete maturation, auditory processing, and neuronal integrity. Furthermore, there is currently great interest in mimicking the biological activity of CNP for therapeutic gain in many of these disparate organ systems. Herein, we provide an overview of the physiology, pathophysiology and pharmacology of CNP in both cardiovascular and non-cardiovascular settings.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001281/pdfft?md5=a6600f580a45edf02b1283f72e0e53df&pid=1-s2.0-S0163725824001281-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141999177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overview of the role of purinergic signaling and insights into its role in cancer therapy 概述嘌呤能信号传导的作用及其在癌症治疗中的作用。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-05 DOI: 10.1016/j.pharmthera.2024.108700

Innovation of cancer therapy has received a dramatic acceleration over the last fifteen years thanks to the introduction of the novel immune checkpoint inhibitors (ICI). On the other hand, the conspicuous scientific knowledge accumulated in purinergic signaling since the early seventies is finally being transferred to the clinic. Several Phase I/II clinical trials are currently underway to investigate the effect of drugs interfering with purinergic signaling as stand-alone or combination therapy in cancer. This is supporting the novel concept of “purinergic immune checkpoint” (PIC) in cancer therapy.

In the present review we will address a) the basic pharmacology and cell biology of the purinergic system; b) principles of its pathophysiology in human diseases; c) implications for cell death, cell proliferation and cancer; d) novel molecular tools to investigate nucleotide homeostasis in the extracellular environment; e) recent developments in the pharmacology of P1, P2 receptors and related ecto-enzymes; f) P1 and P2 ligands as novel diagnostic tools; g) current issues in PIC-based anti-cancer therapy.

This review will provide an appraisal of the current status of purinergic signaling in cancer and will help identify future avenues of development.

由于新型免疫检查点抑制剂(ICI)的问世,癌症疗法的创新在过去十五年中得到了极大的加速。另一方面,自七十年代初以来在嘌呤能信号转导方面积累的显著科学知识终于被应用于临床。目前正在进行几项 I/II 期临床试验,研究干扰嘌呤能信号转导的药物作为独立疗法或联合疗法对癌症的影响。这支持了癌症治疗中 "嘌呤能免疫检查点"(PIC)的新概念。在本综述中,我们将讨论 a) 嘌呤能系统的基础药理学和细胞生物学;b) 嘌呤能系统在人类疾病中的病理生理学原理;c) 嘌呤能系统对细胞死亡、细胞增殖和癌症的影响;d) 研究细胞外环境中核苷酸平衡的新型分子工具;e) P1、P2 受体和相关外酶的药理学最新发展;f) 作为新型诊断工具的 P1 和 P2 配体;g) 基于嘌呤能免疫检查点的抗癌疗法的当前问题。本综述将对癌症中嘌呤能信号转导的现状进行评估,并将有助于确定未来的发展方向。
{"title":"Overview of the role of purinergic signaling and insights into its role in cancer therapy","authors":"","doi":"10.1016/j.pharmthera.2024.108700","DOIUrl":"10.1016/j.pharmthera.2024.108700","url":null,"abstract":"<div><p>Innovation of cancer therapy has received a dramatic acceleration over the last fifteen years thanks to the introduction of the novel immune checkpoint inhibitors (ICI). On the other hand, the conspicuous scientific knowledge accumulated in purinergic signaling since the early seventies is finally being transferred to the clinic. Several Phase I/II clinical trials are currently underway to investigate the effect of drugs interfering with purinergic signaling as stand-alone or combination therapy in cancer. This is supporting the novel concept of “purinergic immune checkpoint” (PIC) in cancer therapy.</p><p>In the present review we will address a) the basic pharmacology and cell biology of the purinergic system; b) principles of its pathophysiology in human diseases; c) implications for cell death, cell proliferation and cancer; d) novel molecular tools to investigate nucleotide homeostasis in the extracellular environment; e) recent developments in the pharmacology of P1, P2 receptors and related ecto-enzymes; f) P1 and P2 ligands as novel diagnostic tools; g) current issues in PIC-based anti-cancer therapy.</p><p>This review will provide an appraisal of the current status of purinergic signaling in cancer and will help identify future avenues of development.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001207/pdfft?md5=a1daa6b93f0294c43639514fa72fb4a9&pid=1-s2.0-S0163725824001207-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders 胰岛素信号的组织特异性激活是肥胖相关代谢紊乱的潜在靶点。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-05 DOI: 10.1016/j.pharmthera.2024.108699

The incidence of obesity is rapidly increasing worldwide. Obesity-associated insulin resistance has long been established as a significant risk factor for obesity-related disorders such as type 2 diabetes and atherosclerosis. Insulin plays a key role in systemic glucose metabolism, with the liver, skeletal muscle, and adipose tissue as the major acting tissues. Insulin receptors and the downstream insulin signaling-related molecules are expressed in various tissues, including vascular endothelial cells, vascular smooth muscle cells, and monocytes/macrophages. In obesity, decreased insulin action is considered a driver for associated disorders. However, whether insulin action has a positive or negative effect on obesity-related disorders depends on the tissue in which it acts. While an enhancement of insulin signaling in the liver increases hepatic fat accumulation and exacerbates dyslipidemia, enhancement of insulin signaling in adipose tissue protects against obesity-related dysfunction of various organs by increasing the capacity for fat accumulation in the adipose tissue and inhibiting ectopic fat accumulation. Thus, this “healthy adipose tissue expansion” by enhancing insulin sensitivity in adipose tissue, but not in the liver, may be an effective therapeutic strategy for obesity-related disorders. To effectively address obesity-related metabolic disorders, the mechanisms of insulin resistance in various tissues of obese patients must be understood and drugs that enhance insulin action must be developed. In this article, we review the potential of interventions that enhance insulin signaling as a therapeutic strategy for obesity-related disorders, focusing on the molecular mechanisms of insulin action in each tissue.

肥胖症的发病率在全球范围内迅速上升。肥胖相关的胰岛素抵抗早已被证实是导致 2 型糖尿病和动脉粥样硬化等肥胖相关疾病的重要风险因素。胰岛素在全身葡萄糖代谢中起着关键作用,肝脏、骨骼肌和脂肪组织是其主要作用组织。胰岛素受体和下游的胰岛素信号相关分子在多种组织中表达,包括血管内皮细胞、血管平滑肌细胞和单核细胞/巨噬细胞。在肥胖症中,胰岛素作用减弱被认为是相关疾病的驱动因素。然而,胰岛素作用对肥胖相关疾病的影响是积极的还是消极的,取决于胰岛素作用的组织。肝脏中的胰岛素信号增强会增加肝脏脂肪堆积,加剧血脂异常,而脂肪组织中的胰岛素信号增强则会增加脂肪组织的脂肪堆积能力,抑制异位脂肪堆积,从而防止各器官出现与肥胖相关的功能障碍。因此,这种通过增强脂肪组织(而非肝脏)的胰岛素敏感性来实现 "健康脂肪组织扩张 "的方法,可能是治疗肥胖相关疾病的一种有效策略。要有效解决与肥胖相关的代谢紊乱问题,就必须了解肥胖患者各种组织的胰岛素抵抗机制,并开发能增强胰岛素作用的药物。在本文中,我们回顾了增强胰岛素信号传导的干预措施作为肥胖相关疾病治疗策略的潜力,重点探讨了胰岛素在各组织中的作用分子机制。
{"title":"Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders","authors":"","doi":"10.1016/j.pharmthera.2024.108699","DOIUrl":"10.1016/j.pharmthera.2024.108699","url":null,"abstract":"<div><p>The incidence of obesity is rapidly increasing worldwide. Obesity-associated insulin resistance has long been established as a significant risk factor for obesity-related disorders such as type 2 diabetes and atherosclerosis. Insulin plays a key role in systemic glucose metabolism, with the liver, skeletal muscle, and adipose tissue as the major acting tissues. Insulin receptors and the downstream insulin signaling-related molecules are expressed in various tissues, including vascular endothelial cells, vascular smooth muscle cells, and monocytes/macrophages. In obesity, decreased insulin action is considered a driver for associated disorders. However, whether insulin action has a positive or negative effect on obesity-related disorders depends on the tissue in which it acts. While an enhancement of insulin signaling in the liver increases hepatic fat accumulation and exacerbates dyslipidemia, enhancement of insulin signaling in adipose tissue protects against obesity-related dysfunction of various organs by increasing the capacity for fat accumulation in the adipose tissue and inhibiting ectopic fat accumulation. Thus, this “healthy adipose tissue expansion” by enhancing insulin sensitivity in adipose tissue, but not in the liver, may be an effective therapeutic strategy for obesity-related disorders. To effectively address obesity-related metabolic disorders, the mechanisms of insulin resistance in various tissues of obese patients must be understood and drugs that enhance insulin action must be developed. In this article, we review the potential of interventions that enhance insulin signaling as a therapeutic strategy for obesity-related disorders, focusing on the molecular mechanisms of insulin action in each tissue.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001190/pdfft?md5=e581979ebbd453ee2ff079fb7585ccff&pid=1-s2.0-S0163725824001190-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141900438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response 进入 TiME 机器:肿瘤免疫微环境中与年龄相关的变化如何影响黑色素瘤的进展和治疗反应?
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-08-03 DOI: 10.1016/j.pharmthera.2024.108698

Melanoma is the deadliest form of skin cancer in the United States, with its incidence rates rising in older populations. As the immune system undergoes age-related changes, these alterations can significantly influence tumor progression and the effectiveness of cancer treatments. Recent advancements in understanding immune checkpoint molecules have paved the way for the development of innovative immunotherapies targeting solid tumors. However, the aging tumor microenvironment can play a crucial role in modulating the response to these immunotherapeutic approaches. This review seeks to examine the intricate relationship between age-related changes in the immune system and their impact on the efficacy of immunotherapies, particularly in the context of melanoma. By exploring this complex interplay, we hope to elucidate potential strategies to optimize treatment outcomes for older patients with melanoma, and draw parallels to other cancers.

黑色素瘤是美国最致命的皮肤癌,其发病率在老年人群中不断上升。随着免疫系统发生与年龄相关的变化,这些变化会极大地影响肿瘤的发展和癌症治疗的效果。最近在了解免疫检查点分子方面取得的进展为开发针对实体瘤的创新免疫疗法铺平了道路。然而,老化的肿瘤微环境在调节对这些免疫治疗方法的反应方面起着至关重要的作用。本综述旨在探讨免疫系统中与年龄有关的变化及其对免疫疗法疗效的影响之间错综复杂的关系,尤其是在黑色素瘤的情况下。我们希望通过探讨这种复杂的相互作用,阐明优化老年黑色素瘤患者治疗效果的潜在策略,并将其与其他癌症进行比较。
{"title":"Entering the TiME machine: How age-related changes in the tumor immune microenvironment impact melanoma progression and therapy response","authors":"","doi":"10.1016/j.pharmthera.2024.108698","DOIUrl":"10.1016/j.pharmthera.2024.108698","url":null,"abstract":"<div><p>Melanoma is the deadliest form of skin cancer in the United States, with its incidence rates rising in older populations. As the immune system undergoes age-related changes, these alterations can significantly influence tumor progression and the effectiveness of cancer treatments. Recent advancements in understanding immune checkpoint molecules have paved the way for the development of innovative immunotherapies targeting solid tumors. However, the aging tumor microenvironment can play a crucial role in modulating the response to these immunotherapeutic approaches. This review seeks to examine the intricate relationship between age-related changes in the immune system and their impact on the efficacy of immunotherapies, particularly in the context of melanoma. By exploring this complex interplay, we hope to elucidate potential strategies to optimize treatment outcomes for older patients with melanoma, and draw parallels to other cancers.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing 克服癌症抗药性需要针对异常剪接的新策略。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-23 DOI: 10.1016/j.pharmthera.2024.108697

Abnormal gene alternative splicing (AS) events are strongly associated with cancer progression. Here, we summarize AS events that contribute to the development of drug resistance and classify them into three categories: alternative cis-splicing (ACS), alternative trans-splicing (ATS), and alternative back-splicing (ABS). The regulatory mechanisms underlying AS processes through cis-acting regulatory elements and trans-acting factors are comprehensively described, and the distinct functions of spliced variants, including linear spliced variants derived from ACS, chimeric spliced variants arising from ATS, and circRNAs generated through ABS, are discussed. The identification of dysregulated spliced variants, which contribute to drug resistance and hinder effective cancer treatment, suggests that abnormal AS processes may together serve as a precise regulatory mechanism enabling drug-resistant cancer cell survival or, alternatively, represent an evolutionary pathway for cancer cells to adapt to changes in the external environment. Moreover, this review summarizes recent advancements in treatment approaches targeting AS-associated drug resistance, focusing on cis-acting regulatory elements, trans-acting factors, and specific spliced variants. Collectively, gaining an in-depth understanding of the mechanisms underlying aberrant alternative splicing events and developing strategies to target this process hold great promise for overcoming cancer drug resistance.

异常基因替代剪接(AS)事件与癌症进展密切相关。在此,我们总结了导致耐药性发生的基因替代剪接事件,并将其分为三类:替代顺式剪接(ACS)、替代反式剪接(ATS)和替代逆式剪接(ABS)。研究全面阐述了通过顺式作用调控元件和反式作用因子实现的AS过程的调控机制,并讨论了剪接变体的不同功能,包括ACS产生的线性剪接变体、ATS产生的嵌合剪接变体和ABS产生的circRNA。剪接变体的失调会导致耐药性并阻碍癌症的有效治疗,其鉴定结果表明,异常的AS过程可能是使耐药癌细胞存活的一种精确调控机制,或者是癌细胞适应外部环境变化的一种进化途径。此外,本综述还总结了针对AS相关耐药性的治疗方法的最新进展,重点关注顺式作用元件、反式作用因子和特定剪接变体。总之,深入了解异常替代剪接事件的内在机制并开发针对这一过程的策略,将为克服癌症耐药性带来巨大希望。
{"title":"Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing","authors":"","doi":"10.1016/j.pharmthera.2024.108697","DOIUrl":"10.1016/j.pharmthera.2024.108697","url":null,"abstract":"<div><p>Abnormal gene alternative splicing (AS) events are strongly associated with cancer progression. Here, we summarize AS events that contribute to the development of drug resistance and classify them into three categories: alternative <em>cis</em>-splicing (ACS), alternative <em>trans</em>-splicing (ATS), and alternative back-splicing (ABS). The regulatory mechanisms underlying AS processes through <em>cis-</em>acting regulatory elements and <em>trans</em>-acting factors are comprehensively described, and the distinct functions of spliced variants, including linear spliced variants derived from ACS, chimeric spliced variants arising from ATS, and circRNAs generated through ABS, are discussed. The identification of dysregulated spliced variants, which contribute to drug resistance and hinder effective cancer treatment, suggests that abnormal AS processes may together serve as a precise regulatory mechanism enabling drug-resistant cancer cell survival or, alternatively, represent an evolutionary pathway for cancer cells to adapt to changes in the external environment. Moreover, this review summarizes recent advancements in treatment approaches targeting AS-associated drug resistance, focusing on <em>cis</em>-acting regulatory elements, <em>trans</em>-acting factors, and specific spliced variants. Collectively, gaining an in-depth understanding of the mechanisms underlying aberrant alternative splicing events and developing strategies to target this process hold great promise for overcoming cancer drug resistance.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141722806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections 预防和治疗尿路感染中抗生素耐药性上升的现状和新展望。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-06 DOI: 10.1016/j.pharmthera.2024.108688

Antibiotic-resistant bacteria are currently an important public health concern posing a serious threat due to their resistance to the current arsenal of antibiotics. Uropathogens Escherichia coli (UPEC), Proteus mirabilis, Klebsiella pneumoniae and Enterococcus faecalis, antibiotic-resistant gram-negative bacteria, cause serious cases of prolonged UTIs, increasing healthcare costs and potentially even leading to the death of an affected patient. This review discusses current knowledge about the increasing resistance to currently recommended antibiotics for UTI therapy, as well as novel therapeutic options. Traditional antibiotics are still a part of the therapy guidelines for UTIs, although they are often not effective and have serious side effects. Hence, novel drugs are being developed, such as combinations of β-lactam antibiotics with cephalosporins and carbapenems. Siderophoric cephalosporins, such as cefiderocol, have shown potential in the treatment of individuals with significant gram-negative bacterial infections, as well as aminoglycosides, fluoroquinolones and tetracyclines that are also undergoing clinical trials. The use of cranberry and probiotics is another potential curative and preventive method that has shown antimicrobial and anti-inflammatory effects. However, further studies are needed to assess the efficacy and safety of probiotics containing cranberry extract for UTI prevention and treatment. An emerging novel approach for UTI treatment is the use of immuno-prophylactic vaccines, as well as different nanotechnology solutions such as nanoparticles (NP). NP have the potential to be used as delivery systems for drugs to specific targets. Furthermore, nanotechnology could enable the development of nano antibiotics with improved features by the application of different NPs in their structure, such as gold and copper NPs. However, further high-quality research is required for the synthesis and testing of these novel molecules, such as safety evaluation and pharmacovigilance.

抗生素耐药细菌是当前公共卫生的一个重要问题,由于它们对现有抗生素库产生耐药性,因此构成了严重威胁。尿路病原菌大肠埃希菌(UPEC)、奇异变形杆菌、肺炎克雷伯菌和粪肠球菌是耐抗生素革兰氏阴性菌,它们会导致严重的长期UTI病例,增加医疗成本,甚至可能导致患者死亡。这篇综述讨论了有关目前推荐用于治疗尿毒症的抗生素耐药性不断增加的现有知识,以及新的治疗方案。传统抗生素仍然是尿毒症治疗指南的一部分,尽管它们往往效果不佳且有严重的副作用。因此,人们正在开发新型药物,如β-内酰胺类抗生素与头孢菌素和碳青霉烯类的复方制剂。嗜苷头孢菌素(如头孢克洛)已显示出治疗严重革兰氏阴性菌感染患者的潜力,氨基糖苷类、氟喹诺酮类和四环素类药物也正在进行临床试验。使用蔓越莓和益生菌是另一种潜在的治疗和预防方法,已显示出抗菌和消炎作用。然而,还需要进一步的研究来评估含有蔓越莓提取物的益生菌在预防和治疗 UTI 方面的有效性和安全性。一种新出现的治疗尿毒症的新方法是使用免疫预防疫苗以及不同的纳米技术解决方案,如纳米颗粒(Nanoparticles)。纳米颗粒有可能被用作向特定靶点输送药物的系统。此外,通过在纳米抗生素的结构中应用不同的纳米粒子(如金和铜纳米粒子),纳米技术还能开发出功能更强的纳米抗生素。不过,这些新型分子的合成和测试,如安全性评估和药物警戒,还需要进一步的高质量研究。
{"title":"Current state and novel outlook on prevention and treatment of rising antibiotic resistance in urinary tract infections","authors":"","doi":"10.1016/j.pharmthera.2024.108688","DOIUrl":"10.1016/j.pharmthera.2024.108688","url":null,"abstract":"<div><p>Antibiotic-resistant bacteria are currently an important public health concern posing a serious threat due to their resistance to the current arsenal of antibiotics. Uropathogens <em>Escherichia coli (UPEC), Proteus mirabilis, Klebsiella pneumoniae</em> and <em>Enterococcus faecalis</em>, antibiotic-resistant gram-negative bacteria, cause serious cases of prolonged UTIs, increasing healthcare costs and potentially even leading to the death of an affected patient. This review discusses current knowledge about the increasing resistance to currently recommended antibiotics for UTI therapy, as well as novel therapeutic options. Traditional antibiotics are still a part of the therapy guidelines for UTIs, although they are often not effective and have serious side effects. Hence, novel drugs are being developed, such as combinations of β-lactam antibiotics with cephalosporins and carbapenems. Siderophoric cephalosporins, such as cefiderocol, have shown potential in the treatment of individuals with significant gram-negative bacterial infections, as well as aminoglycosides, fluoroquinolones and tetracyclines that are also undergoing clinical trials. The use of cranberry and probiotics is another potential curative and preventive method that has shown antimicrobial and anti-inflammatory effects. However, further studies are needed to assess the efficacy and safety of probiotics containing cranberry extract for UTI prevention and treatment. An emerging novel approach for UTI treatment is the use of immuno-prophylactic vaccines, as well as different nanotechnology solutions such as nanoparticles (NP). NP have the potential to be used as delivery systems for drugs to specific targets. Furthermore, nanotechnology could enable the development of nano antibiotics with improved features by the application of different NPs in their structure, such as gold and copper NPs. However, further high-quality research is required for the synthesis and testing of these novel molecules, such as safety evaluation and pharmacovigilance.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001086/pdfft?md5=04c16e2d669acf095ccda39eb8fb74ad&pid=1-s2.0-S0163725824001086-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141553851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacological interventions for intraplaque neovascularization in atherosclerosis 针对动脉粥样硬化斑块内新生血管的药物干预。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-06 DOI: 10.1016/j.pharmthera.2024.108685
Azizah Ugusman , Nur Syahidah Nor Hisam , Nur Syakirah Othman , Nur Najmi Mohamad Anuar , Adila A. Hamid , Jaya Kumar , Maisarah Md Razmi , Amilia Aminuddin

Advanced atherosclerosis is linked to plaque instability, which can result in rupture and the onset of a heart attack. Evidence gathered from human atheroma plaques indicates that intraplaque neovascularization poses a risk to plaque stability and may lead to plaque hemorrhage. Hence, targeting the neovascularization within the atheroma plaque has the potential to mitigate the plaque's vulnerability. While neovascularization has been extensively explored in the context of cancer, research on pharmacological inhibition of this phenomenon in atherosclerosis remains limited. This systematic review aimed to comprehensively assess current and emerging pharmacological interventions for inhibiting intraplaque neovascularization in preclinical settings. Electronic databases (Web of Science, PubMed, Scopus, and Ovid) were searched from January 2013 until February 1, 2024. Preclinical studies reporting the effect of any pharmacological interventions targeting intraplaque neovascularization were included. A total of 10 articles involving in vivo animal studies were eligible for inclusion, with five of them incorporating in vitro experiments to complement their in vivo findings. The pharmacological interventions studied were axitinib, ghrelin, K5, rosuvastatin, atorvastatin, 3PO, everolimus, melatonin, Si-Miao-Yong-A, and protocatechuic aldehyde. All the interventions showed a positive impact in inhibiting intraplaque neovascularization in various atherosclerotic animal models through various signaling pathways. This review provides valuable insights into pharmacological approaches to attenuate intraplaque neovascularization that could serve as a promising therapeutic avenue to enhance plaque stability.

晚期动脉粥样硬化与斑块不稳定有关,斑块不稳定可导致破裂和心脏病发作。从人类动脉粥样斑块中收集的证据表明,斑块内新生血管对斑块的稳定性构成风险,并可能导致斑块出血。因此,针对动脉粥样斑块内的新生血管有可能减轻斑块的脆弱性。虽然在癌症方面对新生血管进行了广泛的探讨,但在动脉粥样硬化中对这一现象进行药理抑制的研究仍然有限。本系统综述旨在全面评估在临床前环境中抑制斑块内新生血管的现有和新兴药理学干预措施。检索了从 2013 年 1 月至 2024 年 2 月 1 日的电子数据库(Web of Science、PubMed、Scopus 和 Ovid)。纳入了报告任何针对斑块内新生血管的药物干预效果的临床前研究。共有10篇涉及体内动物研究的文章符合纳入条件,其中5篇结合了体外实验以补充体内研究结果。研究的药物干预措施包括阿昔替尼、胃泌素、K5、罗苏伐他汀、阿托伐他汀、3PO、依维莫司、褪黑素、Si-Miao-Yong-A 和原儿茶醛。所有干预措施都通过不同的信号传导途径,对抑制各种动脉粥样硬化动物模型斑块内新生血管的形成产生了积极影响。这篇综述为减轻斑块内新生血管的药理学方法提供了有价值的见解,可作为增强斑块稳定性的一种有前途的治疗途径。
{"title":"Pharmacological interventions for intraplaque neovascularization in atherosclerosis","authors":"Azizah Ugusman ,&nbsp;Nur Syahidah Nor Hisam ,&nbsp;Nur Syakirah Othman ,&nbsp;Nur Najmi Mohamad Anuar ,&nbsp;Adila A. Hamid ,&nbsp;Jaya Kumar ,&nbsp;Maisarah Md Razmi ,&nbsp;Amilia Aminuddin","doi":"10.1016/j.pharmthera.2024.108685","DOIUrl":"10.1016/j.pharmthera.2024.108685","url":null,"abstract":"<div><p>Advanced atherosclerosis is linked to plaque instability, which can result in rupture and the onset of a heart attack. Evidence gathered from human atheroma plaques indicates that intraplaque neovascularization poses a risk to plaque stability and may lead to plaque hemorrhage. Hence, targeting the neovascularization within the atheroma plaque has the potential to mitigate the plaque's vulnerability. While neovascularization has been extensively explored in the context of cancer, research on pharmacological inhibition of this phenomenon in atherosclerosis remains limited. This systematic review aimed to comprehensively assess current and emerging pharmacological interventions for inhibiting intraplaque neovascularization in preclinical settings. Electronic databases (Web of Science, PubMed, Scopus, and Ovid) were searched from January 2013 until February 1, 2024. Preclinical studies reporting the effect of any pharmacological interventions targeting intraplaque neovascularization were included. A total of 10 articles involving in vivo animal studies were eligible for inclusion, with five of them incorporating in vitro experiments to complement their in vivo findings. The pharmacological interventions studied were axitinib, ghrelin, K5, rosuvastatin, atorvastatin, 3PO, everolimus, melatonin, Si-Miao-Yong-A, and protocatechuic aldehyde. All the interventions showed a positive impact in inhibiting intraplaque neovascularization in various atherosclerotic animal models through various signaling pathways. This review provides valuable insights into pharmacological approaches to attenuate intraplaque neovascularization that could serve as a promising therapeutic avenue to enhance plaque stability.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Vitamins and fatty acids against chemotherapy-induced intestinal mucositis 维生素和脂肪酸可预防化疗引起的肠粘膜炎。
IF 12 1区 医学 Q1 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-05 DOI: 10.1016/j.pharmthera.2024.108689

Chemotherapy has allowed an increase in cancer survivorship, but it causes important adverse effects. Mucositis affecting the gastrointestinal tract is one of the main problems acutely caused by many antineoplastic drugs, such as 5-fluorouracil or methotrexate. Mucositis may cause pain, diarrhea, anorexia, weight loss, systemic infections and even death. This narrative review focuses on intestinal mucositis and the role that some nutraceuticals, namely vitamins (both lipid- and water-soluble) as well as fatty acids (FAs) and lipid-based products, can have in it. In preclinical (cell cultures, animal models) and/or human studies, vitamins A, D, E, B2, B9 and C, omega-3 long-chain FAs (eicosapentaenoic, docosahexaenoic, conjugated linoleic acid), short-chain FAs (mainly butyrate), medium-chain FAs (capric acid), and different lipid-based products (emu oil, extra-virgin olive oil, lipid replacement therapy), enriched in beneficial FAs and natural antioxidants, were shown to exert beneficial effects (both preventative and palliative) against chemotherapy-induced intestinal mucositis. Although the exact mechanisms of action involved in these effects are not yet well known, our review highlights the interest of investigating on diet and nutrition to implement scientifically robust strategies to improve protection of cancer patients against chemotherapy-induced adverse effects.

化疗提高了癌症患者的生存率,但也带来了一些重要的不良反应。影响胃肠道的黏膜炎是许多抗肿瘤药物(如 5-氟尿嘧啶或甲氨蝶呤)引起的主要急性问题之一。粘膜炎可能导致疼痛、腹泻、厌食、体重减轻、全身感染甚至死亡。这篇叙述性综述的重点是肠粘膜炎以及一些营养保健品,即维生素(脂溶性和水溶性)、脂肪酸(FAs)和脂基产品在肠粘膜炎中的作用。在临床前(细胞培养、动物模型)和/或人体研究中,维生素 A、D、E、B2、B9 和 C、ω-3 长链脂肪酸(二十碳五烯酸、二十二碳六烯酸、共轭亚油酸)、短链脂肪酸(主要是丁酸)、中链脂肪酸(癸酸)、研究表明,富含有益脂肪酸和天然抗氧化剂的不同脂质产品(鸸鹋油、特级初榨橄榄油、脂质替代疗法)对化疗引起的肠道粘膜炎具有有益作用(预防和缓解)。虽然这些效果的确切作用机制尚不清楚,但我们的综述强调了对饮食和营养进行研究,以实施科学可靠的策略来提高癌症患者对化疗引起的不良反应的保护的兴趣。
{"title":"Vitamins and fatty acids against chemotherapy-induced intestinal mucositis","authors":"","doi":"10.1016/j.pharmthera.2024.108689","DOIUrl":"10.1016/j.pharmthera.2024.108689","url":null,"abstract":"<div><p>Chemotherapy has allowed an increase in cancer survivorship, but it causes important adverse effects. Mucositis affecting the gastrointestinal tract is one of the main problems acutely caused by many antineoplastic drugs, such as 5-fluorouracil or methotrexate. Mucositis may cause pain, diarrhea, anorexia, weight loss, systemic infections and even death. This narrative review focuses on intestinal mucositis and the role that some nutraceuticals, namely vitamins (both lipid- and water-soluble) as well as fatty acids (FAs) and lipid-based products, can have in it. In preclinical (cell cultures, animal models) and/or human studies, vitamins A, D, E, B2, B9 and C, omega-3 long-chain FAs (eicosapentaenoic, docosahexaenoic, conjugated linoleic acid), short-chain FAs (mainly butyrate), medium-chain FAs (capric acid), and different lipid-based products (emu oil, extra-virgin olive oil, lipid replacement therapy), enriched in beneficial FAs and natural antioxidants, were shown to exert beneficial effects (both preventative and palliative) against chemotherapy-induced intestinal mucositis. Although the exact mechanisms of action involved in these effects are not yet well known, our review highlights the interest of investigating on diet and nutrition to implement scientifically robust strategies to improve protection of cancer patients against chemotherapy-induced adverse effects.</p></div>","PeriodicalId":402,"journal":{"name":"Pharmacology & Therapeutics","volume":null,"pages":null},"PeriodicalIF":12.0,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163725824001098/pdfft?md5=ffd1117625949a41758bb70bcd328b2a&pid=1-s2.0-S0163725824001098-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141553852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmacology & Therapeutics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1